MCID: HMN014
MIFTS: 55

Human Immunodeficiency Virus Infectious Disease

Categories: Immune diseases, Infectious diseases

Aliases & Classifications for Human Immunodeficiency Virus Infectious Disease

MalaCards integrated aliases for Human Immunodeficiency Virus Infectious Disease:

Name: Human Immunodeficiency Virus Infectious Disease 12 15
Hiv Infections 15

Classifications:



External Ids:

Disease Ontology 12 DOID:526
ICD9CM 34 042 042-042.99
MeSH 43 D015658
NCIt 49 C3108
SNOMED-CT 67 86406008
ICD10 32 B20 B20-B20
UMLS 71 C0019693

Summaries for Human Immunodeficiency Virus Infectious Disease

Disease Ontology : 12 A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.

MalaCards based summary : Human Immunodeficiency Virus Infectious Disease, also known as hiv infections, is related to human immunodeficiency virus type 1 and aids dementia complex. An important gene associated with Human Immunodeficiency Virus Infectious Disease is CCR5 (C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lercanidipine and Candesartan cilexetil have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and bone, and related phenotypes are cellular and hematopoietic system

Related Diseases for Human Immunodeficiency Virus Infectious Disease

Diseases related to Human Immunodeficiency Virus Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1832)
# Related Disease Score Top Affiliating Genes
1 human immunodeficiency virus type 1 33.9 TNF ITIH4 IL7 IL2 IL10 IFNG
2 aids dementia complex 33.6 TNF ITIH4 CXCR4 CXCL12 B2M
3 cervical cancer 33.3 TNF IL7 IL2 IL10 IFNG CXCR4
4 epidermodysplasia verruciformis 1 33.2 IL7 CXCR4 CD4
5 acquired immunodeficiency syndrome 33.0 TNF ITIH4 IL2 IL10 IFNG CD9
6 macs syndrome 32.9 TNF IL10 IFNG CD4
7 syphilis 32.7 CD4 CD209 CCR5 B2M
8 candidiasis 32.6 TNF IL2 IL10 IFNG
9 toxoplasmosis 32.4 TNF IL10 IFNG CCR5 CCL3
10 diarrhea 32.4 TNF IL2 IL10 IFNG
11 exanthem 32.3 TNF IL2 IL10 CD4
12 pulmonary tuberculosis 32.3 TNF IL2 IL10 IFNG CCL4 CCL3
13 cryptococcosis 32.3 TNF IL10 IFNG CD4
14 pneumonia 32.3 TNF IL2 IL10 IFNG CCL5 CCL3
15 pneumocystosis 32.2 TNF CD4 CCR5
16 chlamydia 32.2 TNF IL10 IFNG
17 leishmaniasis 32.2 TNF IL2 IL10 IFNG CD28 CCR5
18 bacterial pneumonia 32.2 TNF IL10 CD4 CCL3
19 herpes zoster 32.2 TNF IL2 IL10 IFNG CD4 CCR5
20 viral hepatitis 32.2 TNF IL2 IL10 IFNG
21 bacterial infectious disease 32.2 TNF ITIH4 IL10 IFNG CD4 CCL4
22 histoplasmosis 32.1 TNF IFNG CD4
23 visceral leishmaniasis 32.1 TNF IL2 IL10 IFNG CD28
24 meningitis 32.1 TNF IL2 IL10 IFNG CXCL12 CCL5
25 chickenpox 32.1 TNF IL2 IL10 IFNG CD4
26 cytomegalovirus infection 32.1 TNF CCL5 CCL3 B2M
27 peripheral nervous system disease 32.1 TNF IL2 IL10 IFNG CD4 B2M
28 hepatitis a 32.0 TNF IL2 IL10 IFNG
29 measles 32.0 TNF IL2 IFNG CD209 CCL5
30 hepatitis c 32.0 TNF IL10 IFNG CCR5
31 cytomegalovirus retinitis 32.0 TNF IL10 IFNG CXCL12 CD9 CD4
32 lymphopenia 32.0 IL7R IL7 IL2 IL10 IFNG CD28
33 mycobacterium tuberculosis 1 32.0 TNF IL7 IL10 IFNG CD4 CD209
34 lung disease 32.0 TNF IL10 IFNG CXCR4 CCR5 CCL5
35 thrombocytopenia 32.0 TNF IL7 IL2 IL10 IFNG CXCL12
36 tetanus 32.0 TNF IL7R IL2 IL10 IFNG
37 progressive multifocal leukoencephalopathy 32.0 TNF IL2 CD4
38 allergic hypersensitivity disease 32.0 TNF IL2 IL10 IFNG CD4 CCL5
39 encephalitis 31.9 TNF ITIH4 IL10 ERVW-1 CXCR4 CD209
40 lymphadenitis 31.9 TNF IL10 IFNG CD4 CD209
41 gingivitis 31.9 TNF IL2 IL10 IFNG CCL5
42 extrapulmonary tuberculosis 31.9 TNF IL10 IFNG CD4
43 end stage renal failure 31.9 TNF IL2 CCR5 CCL5
44 multidrug-resistant tuberculosis 31.9 TNF IL10 IFNG CD4
45 meningoencephalitis 31.9 TNF IL10 CD4 CCL5 B2M
46 neuroretinitis 31.8 IFNG CD4
47 genital herpes 31.8 IL10 CD4 CCL5
48 lymphoma, non-hodgkin, familial 31.8 TNF IL7 IL2 IL10 CXCR4 CXCL12
49 trichomoniasis 31.8 TNF IL2 CD4 CCR5
50 vascular disease 31.8 TNF IL2 IL10 IFNG CXCL12 CD4

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Infectious Disease:



Diseases related to Human Immunodeficiency Virus Infectious Disease

Symptoms & Phenotypes for Human Immunodeficiency Virus Infectious Disease

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Infectious Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 B2M CCR5 CD28 CD38 CD4 CD9
2 hematopoietic system MP:0005397 10.24 B2M CCL5 CCR5 CD28 CD38 CD4
3 endocrine/exocrine gland MP:0005379 10.22 B2M CD28 CD38 CD4 CD9 CXCR4
4 immune system MP:0005387 10.2 B2M CCL5 CCR5 CD28 CD38 CD4
5 digestive/alimentary MP:0005381 10.09 B2M CCR5 CD28 CD4 CXCR4 IFNG
6 neoplasm MP:0002006 9.9 B2M CCR5 CD28 CD9 CXCR4 IFNG
7 liver/biliary system MP:0005370 9.86 B2M CCR5 CXCL12 IFNG IL10 IL2
8 no phenotypic analysis MP:0003012 9.5 CD4 CXCL12 IFNG IL10 IL2 IL7
9 reproductive system MP:0005389 9.32 B2M CCR5 CD9 CXCL12 CXCR4 IFNG

Drugs & Therapeutics for Human Immunodeficiency Virus Infectious Disease

Drugs for Human Immunodeficiency Virus Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 783)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
2
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
3
Methadone Approved Phase 4 76-99-3 4095
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
5
Tipranavir Approved, Investigational Phase 4 174484-41-4 65027
6
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
7
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
8
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
9
Amprenavir Approved, Investigational Phase 4 161814-49-9 65016
10
Didanosine Approved Phase 4 69655-05-6 50599
11
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
12
Indinavir Approved Phase 4 150378-17-9 5362440
13
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
14
Zinc Approved, Investigational Phase 4 7440-66-6 32051
15
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
16
Zalcitabine Approved, Investigational Phase 4 7481-89-2 24066
17
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
18
Pravastatin Approved Phase 4 81093-37-0 54687
19
Fosamprenavir Approved Phase 4 226700-79-4 131536
20
Echinacea Approved, Experimental Phase 4
21
Famotidine Approved Phase 4 76824-35-6 3325
22
leucovorin Approved Phase 4 58-05-9 6006 143
23
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
24
Sulfamethoxazole Approved Phase 4 723-46-6 5329
25
Atovaquone Approved Phase 4 95233-18-4 74989
26
Lumefantrine Approved Phase 4 82186-77-4 6437380
27
Artemether Approved Phase 4 71963-77-4 119380 68911
28
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
29
Proguanil Approved Phase 4 500-92-5 4923
30
Zoledronic Acid Approved Phase 4 118072-93-8 68740
31
Methyltestosterone Approved Phase 4 58-18-4 6010
32
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
33
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
34
Testosterone enanthate Approved Phase 4 315-37-7 9416
35
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
36
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
37
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
38
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
39
Cytarabine Approved, Experimental, Investigational Phase 4 147-94-4, 65-46-3 6253
40
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
41
Temazepam Approved, Investigational Phase 4 846-50-4 5391
42
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
43
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
44
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
45
carbamide peroxide Approved Phase 4 124-43-6
46
Lithium carbonate Approved Phase 4 554-13-2
47
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
48
Lopinavir Approved Phase 4 192725-17-0 92727
49
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
50
Ofloxacin Approved Phase 4 82419-36-1 4583

Interventional clinical trials:

(show top 50) (show all 4079)
# Name Status NCT ID Phase Drugs
1 Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4 candesartan;lercanidipine
2 Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects Unknown status NCT00759070 Phase 4 Tenofovir + emtricitabine + efavirenz;Tenofovir + emtricitabine + lopinavir/ritonavir
3 Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen. Unknown status NCT00751153 Phase 4 Raltegravir and Atazanavir
4 Pilot, Open-label, Randomized, Single-center Study to Asses a Simplification Strategy From Protease Inhibitors to Raltegravir: Once Daily Isentress (ODIS) Unknown status NCT00941083 Phase 4 Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy)
5 Study of the Immunogenicity and Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Adults Unknown status NCT03041051 Phase 4
6 A Pilot Study of Highly Active Antiretroviral Therapy Using Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Antiretroviral Naive HIV-Infected Subjects Unknown status NCT00740064 Phase 4 Raltegravir and Abacavir/Lamivudine
7 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
8 A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who Are Antiretroviral Therapy Naive Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
9 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
10 Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a "Real Life" Study Unknown status NCT01049685 Phase 4 First-line Antiretroviral Therapy
11 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
12 A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
13 A Randomized Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
14 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
15 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in Patients With HIV. Influence on Morphological and Metabolic Disorders. A Randomized, Open-Label Multicenter Trial. Unknown status NCT00135460 Phase 4 nucleoside analogue sparing HAART regimen
16 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
17 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
18 Pilot Study of the Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection Unknown status NCT01343225 Phase 4 atripla;darunavir ritonavir raltegravir
19 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
20 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
21 Phase IV, Randomized, Open Label, Crossover, Intervention Trial to Investigate the Effect of the Switch of Lopinavir/Ritonavir to Raltegravir on Endothelial Function, Chronic Inflammation, Immune Activation and HIV Replication <50 Copies/ml Unknown status NCT01453933 Phase 4 raltegravir
22 Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
23 Treating HIV-infected Elite Controllers as a Model of HIV Remission Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
24 The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial Unknown status NCT02401828 Phase 4 Dolutegravir
25 Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
26 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
27 Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens With Other PI's/NNRTI's in HIV+ Children and Adolescents With Elevated Lipid Levels Unknown status NCT00940771 Phase 4 Boosted Atazanavir
28 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
29 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
30 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
31 The Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection Unknown status NCT03205566 Phase 4 Raltegravir 400Mg Tab;Lamivudine 150Mg Tablet
32 Development of an HIV Self-testing Intervention to Reduce HIV Risks Among MSM: Taking the Guess Out of Seroguessing Unknown status NCT02999243 Phase 4
33 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
34 Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
35 A Multicenter, Randomized, Open-label, Controlled Study of Nevirapine (VIRAMUNE®) and a Short Course of Prednisone to Determine the Safety and Effectiveness of This Strategy in Preventing Nevirapine (VIRAMUNE®) Associated Rash. Completed NCT02184299 Phase 4 Nevirapine;Prednisone
36 An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) Completed NCT02184078 Phase 4 Nevirapine;Rifabutin
37 An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Fluconazole (DIFLUCAN®) Completed NCT02181946 Phase 4 Fluconazole;Nevirapine
38 Adherence, Efficacy and Tolerance of Once-a-day Nevirapine-based Regimen in HIV-1 Infected Patients Completed NCT00466180 Phase 4
39 Comparison of 2 Alternative Antiretroviral Combinations in HIV Post-exposure Prophylaxis: AZT-3TC (Combivir®) + Lopinavir-ritonavir (Kaletra®) Versus AZT-3TC (Combivir®)+ Atazanavir (Reyataz®). Multicentre, Prospective, Randomized, Open Study Completed NCT00385645 Phase 4 Combivir+Kaletra;Combivir+Reyataz
40 Efficacy and Safety of Switching From AZT to Tenofovir Completed NCT00647244 Phase 4 Tenofovir disoproxil fumarate;Abacavir
41 Comparison Atazanavir/Ritonavir (ATV/r) vs Nevirapine (NVP) Twice a Day (Bid) on Truvada Backbone Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
42 A Randomised Prospective Study Assessing Changes in Neurocognitive Function, Using a Computerised Test Battery, in Treatment Naïve HIV-1 Positive Subjects Commencing Two Different Antiretroviral Regimens Completed NCT00540137 Phase 4 nevirapine;atazanavir/ritonavir
43 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
44 Daily Antiretroviral Therapy (DART-II): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial To Evaluate the Efficacy and Safety fo Stavudine Extended Release (d4T XR) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in Anti-Retroviral Therapy (ART) Naive HIV-Infected Subjects Completed NCT00116116 Phase 4 efavirenz, stavudine extended release, lamivudine
45 A Phase IV 48 Week, Open Label, Pilot Study of Kaletra and Intelence Tablets in Naive Subjects Completed NCT01045369 Phase 4 Kaletra and Intelence Tablets
46 Comparison of Antiretroviral Activity and Immunological Effect of Two Triple Treatments With and Without Protease Inhibitors in naïve HIV-1-infected Patients With CD4 < 100/mm3 Completed NCT00385957 Phase 4 AZT+3TC+IDV+RTV;AZT+3TC+EFV
47 Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on Their HAART Regimen Completed NCT00365612 Phase 4 Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)
48 HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain Completed NCT00685191 Phase 4 Salvage antiretroviral therapy including raltegravir
49 Effect of Enfuvirtide on Lipid and Glucose Metabolism and Mitochondrial Function in Healthy Volunteers Completed NCT00657761 Phase 4 Enfuvirtide;Placebo
50 A Pharmacokinetic Study to Assess Nevirapine Levels in HIV-infected Patients With Impaired Hepatic Function Completed NCT00144248 Phase 4 nevirapine

Search NIH Clinical Center for Human Immunodeficiency Virus Infectious Disease

Genetic Tests for Human Immunodeficiency Virus Infectious Disease

Anatomical Context for Human Immunodeficiency Virus Infectious Disease

MalaCards organs/tissues related to Human Immunodeficiency Virus Infectious Disease:

40
Testes, T Cells, Bone, Liver, B Cells, Monocytes, Heart

Publications for Human Immunodeficiency Virus Infectious Disease

Articles related to Human Immunodeficiency Virus Infectious Disease:

(show top 50) (show all 6478)
# Title Authors PMID Year
1
Rapid detection of HIV-1 p24 antigen using magnetic immuno-chromatography (MICT). 54 61
19482361 2009
2
Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. 54 61
19535523 2009
3
Expression and production of human interleukin-7 in insect cells using baculovirus expression vector system (BEVS). 54 61
18546077 2008
4
Emerging antiviral drugs. 54 61
18764719 2008
5
A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. 54 61
18096673 2008
6
A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection. 54 61
16439866 2006
7
Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection. 54 61
16438645 2006
8
RNAi-directed inhibition of DC-SIGN by dendritic cells: prospects for HIV-1 therapy. 54 61
16353935 2005
9
Association of drug abuse with inhibition of HIV-1 immune responses: studies with long-term of HIV-1 non-progressors. 54 61
14741421 2004
10
Polymorphisms of CCR5 gene in a southern Chinese population and their effects on disease progression in HIV infections. 54 61
12461425 2002
11
Oral mucosal immunity and HIV infection: current status. 54 61
12164661 2002
12
Autoantibodies to TNFalpha in HIV-1 infection: prospects for anti-cytokine vaccine therapy. 54 61
11237281 2001
13
Correlation of virus load and soluble L-selectin, a marker of immune activation, in pediatric HIV-1 infection. 54 61
11101052 2000
14
Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. 54 61
10195751 1999
15
[Early diagnosis of primary HIV infections: using a combined screening test (p24 antigen and anti-HIV antibodies)]. 54 61
10189669 1999
16
Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. 54 61
10231014 1999
17
Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. 54 61
9612607 1998
18
New perspectives for the treatment of HIV infections. 54 61
9646721 1998
19
The role of biological response modifiers on apoptosis in HIV infections and AIDS. 54 61
17451286 1996
20
Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125. 54 61
9079375 1996
21
Zinc and immune function. 54 61
7478075 1995
22
Differential effects of human immunodeficiency virus type 1 envelope protein gp120 on interferon production by mononuclear cells from adults and neonates. 54 61
7583919 1995
23
Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and beta 2-microglobulin are not adequate to estimate time of HIV infection. Multicohort Analysis Project Workshop. Part II. 54 61
7946101 1994
24
[Interferon-gamma. Therapy of recurrent furunculosis in HIV infections]. 54 61
8104915 1993
25
Effectiveness of assays for antibodies to HIV and p24 antigen to detect very recent HIV infections in blood donors. The Retrovirus Study Group of the French Society of Blood Transfusion. 54 61
1492941 1992
26
The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities. 61
31794521 2020
27
A correlation analysis of HHV infection and its predictive factors in an HIV-seropositive population in Yunnan, China. 61
31621089 2020
28
Mobile Dating, Relational Communication, and Motivations for AIDS Risk Reduction among Chinese MSM College Students. 61
30589373 2020
29
Potential health gains in West and Central Africa through savings from lower cost HIV treatment. 61
31996595 2020
30
Signatures of HIV-1 subtype B and C Tat proteins and their effects in the neuropathogenesis of HIV-associated neurocognitive impairments. 61
31837421 2020
31
Gendered powerlessness in at-risk adolescent and young women: an empirical model. 61
32008352 2020
32
Disclosure of HIV Status and HIV Sexual Transmission Behaviors among HIV-Positive Black Men Who Have Sex with Men in the BROTHERS (HPTN 061) Study. 61
32020466 2020
33
Short Communication: The Association of WNT16 Polymorphisms with the CD4+ T Cell Count in the HIV-Infected Population. 61
31623455 2020
34
Latent classes of sexual risk and corresponding STI and HIV positivity among MSM attending centres for sexual health in the Netherlands. 61
31221743 2020
35
Development of a prognostic tool exploring female adolescent risk for HIV prevention and PrEP in rural South Africa, a generalised epidemic setting. 61
31326947 2020
36
Mentor Mothers Zithulele: exploring the role of a peer mentorship programme in rural PMTCT care in Zithulele, Eastern Cape, South Africa. 61
30102134 2020
37
A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy. 61
31352645 2020
38
Aging, sex, inflammation, frailty, and CMV and HIV infections. 61
31843200 2020
39
Sero-prevalence ABO and Rh blood groups and their associated Transfusion-Transmissible Infections among Blood Donors in the Central Region of Saudi Arabia. 61
31953019 2020
40
Substance Use and Sexual Risk Behavior Among Male and Transgender Women Sex Workers at the Prostitution Outreach Center in Amsterdam, the Netherlands. 61
31935207 2020
41
Age at first HIV test for MSM at a community health clinic in Los Angeles. 61
31663365 2020
42
Chain Peer Referral Approach for HIV Testing Among Adolescents in Kisumu County, Kenya. 61
31267295 2020
43
Trends in HIV Testing Among US Adults, Aged 18-64 Years, 2011-2017. 61
31595375 2020
44
The changing modes of human immunodeficiency virus transmission and spatial variations among women in a minority prefecture in southwest China: An exploratory study. 61
32028390 2020
45
Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study. 61
31879250 2020
46
Behavioural and environmental influences on adolescent decision making in personal relationships: a qualitative multi-stakeholder exploration in Panama. 61
31711147 2020
47
Current risk factors for HIV infection among blood donors in seven Chinese regions. 61
31912898 2020
48
Can gut microbiota of men who have sex with men influence HIV transmission? 61
32036739 2020
49
Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. 61
31753763 2020
50
An effectiveness-implementation hybrid type 1 trial assessing the impact of group versus individual antenatal care on maternal and infant outcomes in Malawi. 61
32039721 2020

Variations for Human Immunodeficiency Virus Infectious Disease

Expression for Human Immunodeficiency Virus Infectious Disease

Search GEO for disease gene expression data for Human Immunodeficiency Virus Infectious Disease.

Pathways for Human Immunodeficiency Virus Infectious Disease

Pathways related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 TNF IL7R IL7 IL2 IL10 IFNG
2
Show member pathways
13.89 TNF IL7R IL7 IL2 IL10 CXCR4
3
Show member pathways
13.72 TNF IL7R IL7 IL2 IL10 IFNG
4
Show member pathways
13.62 TNF IL7R IL7 IL2 IL10 IFNG
5
Show member pathways
13.44 TNF IL7R IL7 IL2 IL10 CXCR4
6
Show member pathways
13.41 TNF IL7R IL7 IL2 IL10 IFNG
7
Show member pathways
13.31 TNF IL7R IL7 IL2 IL10 CXCR4
8
Show member pathways
13.16 TNF IL2 IL10 IFNG CCL5 CCL4
9
Show member pathways
13.03 TNF CXCR4 CXCL12 CD4 CCR5 CCL5
10
Show member pathways
12.95 CXCR4 CXCL12 CD4 CCR5 CCL5 CCL4
11
Show member pathways
12.94 TNF IL2 IL10 IFNG CXCR4 CXCL12
12
Show member pathways
12.89 TNF IL2 IFNG CD28 CD209 CCL5
13 12.88 IL7R IL7 IL2 IFNG CXCR4 CXCL12
14
Show member pathways
12.78 TNF IFNG CXCL12 CCL5 CCL4
15
Show member pathways
12.71 TNF IL2 IL10 IFNG CD4 CD28
16
Show member pathways
12.7 TNF IL2 IL10 IFNG CD4 CD28
17
Show member pathways
12.69 TNF IFNG CXCR4 CD4 CCR5
18
Show member pathways
12.67 TNF IL2 IL10 IFNG CD4 CD28
19
Show member pathways
12.62 TNF IL2 IL10 IFNG CD4
20 12.47 TNF IL2 IL10 IFNG CXCR4 CXCL12
21
Show member pathways
12.42 IL7R IL7 IL2 IL10 IFNG
22 12.36 TNF IL2 CD4 B2M
23
Show member pathways
12.35 TNF IL2 IFNG CCL5
24
Show member pathways
12.31 TNF IL2 IL10 CXCR4 CXCL12 CCR5
25
Show member pathways
12.3 TNF IL2 IL10 IFNG CXCL12
26
Show member pathways
12.28 TNF IL10 IFNG CCR5
27 12.26 TNF IL10 IFNG CD209
28
Show member pathways
12.24 TNF IL2 IL10 CD209
29
Show member pathways
12.19 TNF IL2 IL10 IFNG CD4 CD28
30
Show member pathways
12.09 IL2 IFNG CD4 CCR5 CCL4 CCL3